1 min read
Add as a preferred source on GoogleImmix Biopharma Reports $340.9 Million in Cash, Cash Equivalents and Marketable Securities
The company expects the balance at quarter-end to fund operations into mid-2028. Third-quarter operating expenses were $15.9 million.
Immix Biopharma held $340.9 million in cash, cash equivalents and marketable securities as of Sept. 30, 2026, and expects that balance to fund operations into mid-2028.
Operating expenses totaled $15.9 million for the three months ended Sept. 30, the third quarter of 2026.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.